类风湿关节炎合并肿瘤患者改善病情抗风湿药使用推荐意见的系统综述
该系统综述检索电子数据库、指南注册库及相关网站,评价类风湿关节炎(RA)合并肿瘤患者的治疗共识推荐。共纳入39条推荐,半数描述了共识制定过程,AGREE II各领域平均得分33%至87%。推荐普遍认同需谨慎用药,但除肿瘤坏死因子抑制剂在淋巴瘤风险患者中禁用外,DMARDs安全性缺乏共识,多个领域仍无一致意见。
要点
- 多数推荐认同新诊断肿瘤时应暂停RA治疗并重新评估。
- 除淋巴瘤风险患者禁用肿瘤坏死因子抑制剂外,DMARDs安全性推荐不一致。
- 有肿瘤史患者的推荐因药物、肿瘤类型及距诊断时间而异。
核心结论
- RA合并肿瘤患者的治疗推荐常未达到预期方法学标准,虽一致认同需谨慎使用DMARDs,但多个领域仍缺乏共识,亟需研究指导。
研究设计与样本
- 系统综述,检索电子数据库、指南注册库及相关网站,筛选肿瘤特异性的RA管理推荐,由评价者独立按AGREE II工具评价并比较异同。
- 自4,077条唯一题录中识别出39条推荐,其中一半描述了其共识制定过程。
主要发现
- AGREE II各领域平均得分范围为33%至87%。
- 79%的推荐涉及RA的肿瘤风险,并承认总体肿瘤风险增加。
- 除肿瘤坏死因子抑制剂在淋巴瘤风险患者中禁用外,推荐对RA合并肿瘤患者使用DMARDs的安全性意见不一致。
- 多数推荐认同新诊断肿瘤时应停止RA治疗并重新评估。
- 有肿瘤史患者的推荐因药物、肿瘤类型和距肿瘤诊断时间而异,少数推荐覆盖全部问题。
关键数值与推荐
- AGREE II各领域平均得分范围为33%至87%。
- 39条推荐中79%涉及RA肿瘤风险,半数描述了共识制定过程。
临床怎么用
- 临床面对RA合并肿瘤患者应谨慎处方DMARDs,新诊断肿瘤时暂停治疗并重新评估,有肿瘤史者需结合药物、肿瘤类型及时间个体化决策。
局限性
- 推荐常未达到预期方法学标准,且证据匮乏,多个领域缺乏共识,需进一步研究和专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate consensus recommendations regarding management of rheumatoid arthritis (RA) in patients with cancer. METHODS: We searched electronic databases, guideline registries, and relevant web sites for cancer-specific recommendations on RA management. Reviewers independently selected and appraised the recommendations according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. We identified similarities and discrepancies among recommendations. RESULTS: Of 4,077 unique citations, 39 recommendations were identified, of which half described their consensus process. Average scores for the AGREE II domains ranged from 33% to 87%. Cancer risk in RA was addressed in 79% of recommendations, with acknowledgement of increased overall cancer risk. Recommendations did not agree on the safety of using disease-modifying antirheumatic drugs (DMARDs) in RA patients with cancer, except for the contraindication of tumor necrosis factor inhibitors in patients at risk for lymphoma. Most recommendations agreed that RA treatment should be stopped and re-evaluated with a new diagnosis of cancer. Recommendations for patients with a history of cancer differed depending on the drug, cancer type, and time since cancer diagnosis. Few recommendations addressed all issues. CONCLUSION: Recommendations for the treatment of RA in patients with cancer often fail to meet expected methodologic criteria. There was agreement on the need for caution when prescribing DMARDs to these patients. However, several areas continue to lack consensus, and given the paucity of evidence, there is an urgent need for research and expert opinion to guide and standardize the management of RA in patients with cancer.
引用
- Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, et al. Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. Arthritis Care Res (Hoboken). 2020. PMID: 30821928. doi:10.1002/acr.23865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。